Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Zoe K. McQuilten, Ljoudmila Busija, John F. Seymour, Simon Stanworth, Erica M. Wood, Melita Kenealy, Robert Weinkove, on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG)

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Search results